A focused biopharmaceutical company

General presentation for investors and analysts June 2020

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ’theGroup’) provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations,performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share orother financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, bytheir very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially differentfrom those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and theGroup undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materiallyfrom those contained in forward-looking statements, certain of which are beyond the Group’s control, include, among other things: the risk of failure ordelay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development orapproval; the risk of failure to obtain, defend and enforce effective intellectual property (IP) protection and IP challenges by third parties; the impact ofcompetitive pressures including expiry or loss of IP rights, and generic competition; the impact of price controls and reductions; the impact of economic,regulatory and political pressures; the impact of uncertainty and volatility in relation to the UK’s exit from the EU; the risk of failures or delays in the qualityor execution of the Group’s commercial strategies; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in theGroup’s medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology, data protection or cybercrime; therisk of failure of critical processes; any expected gains from productivity initiatives are uncertain; the risk of failure to attract, develop, engage and retain adiverse, talented and capable workforce; the risk of failure to adhere to applicable laws, rules and regulations; the risk of the safety and efficacy of marketedmedicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; the risk of failure to adhere to increasinglystringent anti-bribery and anti-corruption legislation; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure infinancial control or the occurrence of fraud; the risk of unexpected deterioration in the Group’s financial position; and the impact that the COVID-19 globalpandemic may have or continue to have on these risks, on the Group’s ability to continue to mitigate these risks, and on the Group’s operations, financialresults or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.

2

Forward-looking statements disclaimer

3

Strategic priorities

The newstrategicpriorities

Deliver growth and therapy area leadership

Accelerate innovative science

Be a great place to work

Scientific collaborations are key drivers behind the move

4

Cambridge, UK: the global R&D headquarter

Three therapy areas

5

Focused strategy

Respiratory & Immunology

Cardiovascular,Renal & MetabolismOncology

Commitment to further focus the portfolio

Positive pipeline progression supports sustainable growth

6

2019: another year of very significant news flow

1. Type-1 diabetes 2. Respiratory syncytial virus 3. Hypereosinophilic syndrome 4. Eosinophilic oesophagitis 5. Idiopathic pulmonary fibrosis 6. Complete response letter.Indications used above are not complete indications as per medicine label. Analysis based on stock-exchange announcements published on astrazeneca.com.

ForxigaT1D1

approval (EU)

ForxigaT1D

approval (JP)

Qternmet XRT2D

approval (US)

Lynparzabreast cancerapproval (EU)

LynparzaOC 1L (SOLO-1)approval (EU)

BreztriCOPD

approval (JP)

BevespiCOPD

approval (JP)

LynparzaOC 1L (SOLO-1)

approval (JP)

ForxigaT2D CVOT

approval (EU)

TagrissoNSCLC 1L

approval (CN)

roxadustatanaemia CKDapproval (CN)

Fasenraasthma (pen)approval (US)

QtrilmetT2D

approval (EU)

FarxigaT2D CVOT

approval (US)

CalquenceCLL front lineapproval (US)

CalquenceCLL relapsed/refractory

approval (US)

LynparzaOC 1L (SOLO-1)approval (CN)

Enhertubreast cancer 3L

approval (US)

Imfinziunr. SIII NSCLCapproval (CN)

BreztriCOPD

approval (CN)

Lynparzapanc. cancer 1Lapproval (US)

nirsevimabRSV2

PRIME designation(EU)

nirsevimabRSV

breakthrough designation (US)

FasenraHES3

orphan designation (US)

saracatinibIPF5

orphan designation (US)

Lynparzapancreatic cancer

Phase III pos.

BrilintaCAD/T2D

Phase III pos.

selumetinibNF1

breakthrough designation (US)

CalquenceCLL relapsed/refractory

Phase III pos.

Enhertubreast cancer 3LReg. Phase II pos.

ImfinziSCLC

Phase III pos.

CalquenceCLL front linePhase III pos.

roxadustatanaemia from CKD

Phase III safety

Lynparzaprostate cancer 2L

Phase III pos.

TagrissoNSCLC

Phase III pos. (OS)

LynparzaOC 1L (PAOLA-1)

Phase III pos.

FarxigaHF

Phase III pos.

CalquenceCLL

breakthrough designation (US)

FasenraEoE4

orphan designation (US)

anifrolumablupus (SLE)

Phase III pos.

Imfinzi +/- tremeNSCLC 1L (POSEIDON) (PFS)

Phase III pos.

BreztriCOPD (ETHOS)Phase III pos.

Enhertubreast cancer

Priority Review (US)

ImfinziSCLC

Priority Review (US)

selumetinibNF1

Priority Review (US)

FarxigaT1D

CRL6 (US)

PT010COPD

CRL (US)

Imfinzi + tremeNSCLC 1L (NEPTUNE)

Phase III neg.

21Approvals of new medicines or

life-cycle management indications

24Data, regulatory designations

3Unfavourable outcomes

Solid pipeline moving forward

7

Oncology: ‘what’s next’

What’s next What’s nowPhase I/II new medicines, selected Phase III new medicines

adavosertib(WEE11 inhibitor)

solid tumours

monalizumab(NKG2a5 mAb6)

head & neck, colorectal cancers

capivasertibbreast cancer

ceralasertib(ATR2 inhibitor)

solid tumours, blood cancers

oleclumab(CD737 mAb)

lung, pancreatic cancers

savolitinib13

NSCLCtremelimumabmultiple cancers

AZD9833(SERD3, oral)breast cancer

AZD4635(A2AR8 inhibitor)

solid tumoursPhase III lifecycle management, major

AZD5991(MCL14 inhibitor)

blood cancers

danvatirsen(STAT39inhibitor)

bladder, head & neck, lung cancers

Lynparzamultiple cancers

AZD2811(Aurora B inhibitor)

solid tumours, blood cancers

MEDI5752(PD-110 / CTLA-411)

solid tumours

TagrissoNSCLC

Enhertumultiple cancers

AZD0466(Bcl-212/xL)

blood cancers

Imfinzimultiple cancers

Calquencemultiple cancers

1. Tyrosine kinase WEE1 2. Ataxia telangiectasia and rad3-related kinase 3. Selective oestrogen receptor degrader 4. Induced myeloid leukaemia cell differentiation protein 5. Inhibitory cell surface receptor covalently bound to CD94 6. Monoclonal antibody 7. 5'-nucleotidase 8. Adenosine A2A receptor 9. Signal transducer and activator of transcription 3 10. Programmed cell death protein 1 11. cytotoxic T-lymphocyte-associated protein 4 12. B-cell lymphoma 2 13. Potentially pivotal Phase II.

Phase III decision

Highpriority

Expanding pipeline, including immunology

8

BioPharmaceuticals: ‘what’s next’

What’s next What’s nowPhase I/II new medicines, selected Phase III new medicines

cotadutide(GLP-11/glucagon co-agonist)

NASH2

MEDI3506(IL338 mAb)

multiple indications

roxadustatanaemia in CKD

PT027asthma

MEDI7219(GLP-1, oral)

T2D

AZD0449(inhaled JAK9 inhibitor)

asthma

nirsevimabrespiratory syncytial virus

tezepelumabsevere asthma

AZD5718(FLAP3 inhibitor)

CAD4

AZD8154(inhaled PI3Kgδ10 inhibitor)

asthma

brazikumab13

inflammatory bowel diseaseanifrolumab

lupus

AZD8601(VEGF-A mRNA5)

HF

AZD1402(IL4R11 antagonist)

asthmaPhase III lifecycle management, major

AZD2693(PNPLA36 inhibitor)

NASH

AZD7594 (velsecorat)(inhaled/nebulised SGRM12)

asthma, COPD

Fasenramultiple indications

AZD2373(APOL17)

CKD

Farxigamultiple indications

Breztriasthma

New CVRM Respiratory & Immunology 1. Glucagon-like peptide-1 2. Non-alcoholic steatohepatitis 3. 5-Lipoxygenase-activating protein 4. Coronary artery disease 5. Vascular endothelial growth factor A-modified messenger RNA 6. Patatin-like phospholipasedomain-containing protein 3 7. Apolipoprotein L1 8. Interleukin-33 9. Janus kinase 10. Phosphoinositide 3-kinase gamma/delta 11. Interleukin-4 receptor 12. Selective glucocorticoid receptor modulator 13. Subject to the aforementioned regulatory approval.

9

Full pipeline of new medicines (NMEs), 1

Status as of 29 April 2020.

Phase I Phase II Phase III20 new molecular entities 25 new molecular entities 7 new molecular entities

Under review0 new molecular entities

adavosertib#Wee1 ovarian cancer, solid tumours

AZD0466BCL2/xL haematological and solid tumours

AZD1390glioblastoma

AZD2811Aurora solid tumours, haematological malignancies

AZD4573CDK9 haematological malignancies

AZD4635A2aR inhibitor prostate cancer

AZD5153BRD4 haematological and solid tumours

AZD5991MCL1 haematological malignancies

AZD7648#DNAPK solid and haematological tumours

AZD9496SERD ER+ breast

AZD9833SERD ER+ breast

Calquence+ceralasertibBTK+ATR haematological tumours

Calquence+danvatirsenBTK+STAT3 haematological malignancies

capivasertib#AKT breast

capivasertib#AKT prostate

capivasertib+chemotherapy CAPItello-290AKT+chemotherapy mTNBC 1L

Imfinzi# (platform) COASTPD-L1+multiple novel ONC therapies NSCLC

Imfinzi# (platform) NeoCOASTPD-L1++multiple novel ONC therapies NSCLC

Imfinzi#+/-tremelimumab+chemo POSEIDONPD-L1+/-CTLA-4+SoC 1L NSCLC

Imfinzi#+/-tremelimumab+CRT ADRIATICPD-L1+/-CTLA-4+CRT LS-SCLC

Imfinzi#+adavosertib#PD-L1+Wee1 solid tumours

Imfinzi#+AZD4635PD-L1+A2aR prostate cancer

Imfinzi#+AZD5069 or Imfinzi#+ danvatirsen# PD-L1+(CXCR2 or STAT3) HNSCC bladder NSCLC

Imfinzi#+Lynparza# ORIONPD-L1+PARP 1L mNSCLC

Imfinzi#+MEDI0457#PD-L1+DNA HPV vaccine HNSCC

Imfinzi#+monalizumab#PD-L1+NKG2a solid tumours

Imfinzi#+tremelimumab HIMALAYAPD-L1+CTLA-4 1L HCC

Imfinzi#+tremelimumab KESTRELPD-L1+CTLA-4 1L HNSCC

Imfinzi#+tremelimumab+SoC NILEPD-L1+CTLA-4+SoC 1L urothelial cancer

Lynparza#+Imfinzi#+bevacizumab DUO-OPARP+PD-L1+VEGF 1L ovarian

Imfinzi#+RT (platform) CLOVERPD-L1+RT HNSCC NSCLC SCLC

Imfinzi#+tremelimumabPD-L1+CTLA-4 solid tumours

Imfinzi#+tremelimumab+chemoPD-L1+CTLA-4 1L PDAC oesophageal SCLC

Imfinzi+Koselugo (selumetinib)#PD-L1+MEK solid tumours

IPH5201#CD39 solid tumours

MEDI1191IL12 mRNA solid tumours

MEDI2228BCMA ADC multiple myeloma

MEDI5083CD40 ligand fusion protein solid tumours

MEDI5395rNDV GMCSF solid tumours

oleclumab+TagrissoCD73+EGFR EGFRm NSCLC

Imfinzi#+oleclumabPD-L1+CD73 solid tumours

Imfinzi#+tremelimumabPD-L1+CTLA-4 gastric cancer

Imfinzi#+tremelimumabPD-L1+CTLA-4 biliary tract oesophageal

Imfinzi+Lynparza# BAYOUPD-L1+PARP bladder

Lynparza#+adavosertib#PARP+Wee1 solid tumours

Lynparza#+AZD6738 VIOLETTEPARP+ATR breast

Lynparza#+Imfinzi MEDIOLAPARP+PD-L1 ovarian breast gastric SCLC

MEDI5752PD-1/CTLA-4 solid tumours

oleclumab+AZD4635CD73+A2aR prostate cancer

oleclumab+chemo or Imfinzi#+ oleclumab+chemo CD73+chemo or PD-L1+CD73+chemo pancreatic

Tagrisso combo# TATTONEGFR+PD-L1/MEK/MET NSCLC

Tagrisso+savolitinib# SAVANNAHEGFR+MET advanced EGFRm NSCLC

1 Includes novel combinations and additional indications for assets where the lead is not yet launched

# Partnered and/or in collaboration; ¶ Registrational Phase II/III trial

Oncology Precision medicine approach being explored

10

Full pipeline of new medicines (NMEs), 2

Status as of 29 April 2020.

1 Includes novel combinations and additional indications for assets where the lead is not yet launched# Partnered and/or in collaboration; ¶ Registrational Phase II/III trial

BioPharmaceuticals Precision medicine approach being explored

Phase I Phase II Phase III17 new molecular entities 20 new molecular entities 4 new molecular entities

Under review0 new molecular entities

abediterol#LABA asthma / COPD

anifrolumab# Type I IFN receptor SLE SC

anifrolumab# Type I IFN receptor lupus nephritis

anifrolumab# TULIPType I IFN receptor SLE

AZD0284RORg psoriasis / respiratory

AZD0449Inhaled JAK inhibitor asthma

AZD1402#inhaled IL-4Ra asthma

AZD2373Podocyte health nephropathy

AZD2693nonalcoholic steatohepatitis

AZD4041#orexin 1 receptor antagonist opioid use disorder

AZD4831MPO HFpEF

AZD5634inhaled ENaC cystic fibrosis

AZD5718FLAP coronary artery disease

AZD6615hypercholesterolemia CV disease

velsecorat (AZD7594)Inhaled SGRM asthma / COPD

AZD7986#DPP1 COPD

AZD8154Inhaled PI3Kgd asthma

AZD8601#VEGF-A cardiovascular

navafenterol (AZD8871)#MABA COPD

AZD9567SGRM RA / respiratory

nirsevimab#RSV mAb-YTE passive RSV immunisation

PT027ICS/SABA asthma

tezepelumab# NAVIGATOR SOURCETSLP severe uncontrolled asthma

AZD8233hypercholesterolemia cardiovascular

AZD9977MCR cardiovascular

MEDI0618#PAR2 antagonist mAb OA pain

MEDI1341#alpha synuclein parkinson's disease

MEDI1814#amyloidβ alzheimer's disease

MEDI5117# ChinaIL6 YTE rheumatoid arthritis

MEDI6570LOX-1 CV disease

MEDI7219anti-diabetic type-2 diabetes

cotadutideGLP-1/glucagon type-2 diabetes / obesity / NASH

MEDI3506Diabetic kidney disease

MEDI3506IL33 AD / COPD

MEDI5884#cholesterol modulation cardiovascular

MEDI6012LCAT cardiovascular

MEDI7352NGF/TNF OA pain / painful diabetic neuropathy

suvratoxumabα-Toxin Staphylococcus pneumonia

tezepelumab#TSLP atopic dermatitis

tezepelumab#TSLP COPD

verinuradURAT-1 chronic kidney disease

Busy news flow continues; underpinning consistent revenue growth

11

Late-stage pipeline events in the 2020-2021 timeframe

Q2 2020 H2 2020 2021Regulatorydecision

Lynparza- OC (1L) (PAOLA-1) (US)- breast cancer (BRCAm) (CN)- prostate cancer (2L) (US)

Forxiga/Farxiga- T2D CVOT (CN)- HF CVOT (US)Bevespi - COPD (CN)

Imfinzi - ES-SCLC (EU, JP)Lynparza- OC (1L) (PAOLA-1) (EU)- pancreatic cancer (1L, BRCAm) (EU)- prostate cancer (2L) (EU)Calquence - CLL (EU)

Forxiga - HF CVOT (EU, JP, CN)Brilinta/Brilique - CAD/T2D CVOT (US, EU)roxadustat - anaemia in CKD (US)Symbicort - mild asthma (CN)PT010 - COPD (US, EU)

Lynparza - prostate cancer (2L) (JP)Calquence - CLL (JP)Koselugo - NF1 (EU)

Regulatorysubmissionand/oracceptance

Imfinzi - ES-SCLC (CN)Enhertu - gastric cancer (HER2+)

Symbicort - mild asthma (EU)

Tagrisso - adjuvant NSCLC (EGFRm)Lynparza - OC (3L, BRCAm) (US)Enhertu - breast cancer (3L, HER2+) (EU)

Farxiga - CKDanifrolumab - lupus (SLE1)

Imfinzi - unresectable, Stage III NSCLC (PACIFIC-2); adjuvant NSCLC; liver cancer (locoregional)Imfinzi +/- treme - liver cancer (1L); NSCLC (1L) (POSEIDON);head & neck cancer (1L)Lynparza - adjuvant breast cancer; prostate cancer (1L, castration-resistant)Enhertu - breast cancer (2L, HER2+)

Fasenra - nasal polyposisPT027 - asthmatezepelumab - severe asthma

Key Phase IIIdata readouts

- Imfinzi - unresectable, Stage III NSCLC (PACIFIC-2)Imfinzi +/- treme - liver cancer (1L)

Fasenra - nasal polyposisPT027 - asthmatezepelumab - severe asthma

Imfinzi - adjuvant NSCLC; liver cancer (locoregional)Imfinzi +/- treme - NSCLC (1L) (POSEIDON) (OS); head & neck cancer (1L)Lynparza - adjuvant breast cancer; prostate cancer (1L, castration-resistant)Enhertu - breast cancer (3L, HER2+) (Phase III);breast cancer (2L, HER2+); breast cancer (HER2 low)

roxadustat - anaemia in myelodysplastic syndrome

Status as of 29 April 2020. 1. Systemic lupus erythematosus.

12

Q1 2020: 17% revenue growth; new medicines driving growth

New medicinesdrove growth

Strong revenuegrowth continued $m

Q1 2020:

+$1.0bnincremental revenue of the new

medicines compared to Q1 20191

Changes at CER.

Oncology New CVRM Respiratory & ImmunologyAbsolute values at CER. 1. Total revenue for Tagrisso, Imfinzi, Calquence, Enhertu, Farxiga, Brilinta, Lokelma, roxadustat,Fasenra, Bevespi and Breztri and product sales for Lynparza; Bevespi not shown.

14%

11%

18%

22%

5%

17%

Tota

l rev

enue

gro

wth

, per

cen

t

0

100

200

300

400

Oncology now 40% of sales and annualising as a $10bn business

13

Q1 2020: solid growth in all therapy areas and EMs

Q1 2020$m

change%

ratio%

Product sales 6,311 17 100

Oncology 2,502 34 40

New CVRM 1,098 8 17

Respiratory & Immunology 1,551 22 25

Other medicines 1,159 (6) 18

Emerging markets 2,271 16 36

- EMs ex China 857 16 14

- China 1,413 17 22

Product sales at actual exchange rates; changes at CER. 1. Emerging markets.

R&D productivity & focus drive decisions

14

Strategic value-creation framework

R&D productivity

Focus on three main therapy

areas‘Following the science’leads to innovationin and outside areas offocus

OncologyCVRM - Cardiovascular,Renal & MetabolismRespiratory & Immunology

Collaboration1

(milestones/royalty)Accelerate/enhance value; or new

medicines outside focus

Product Sales(Including Growth Platforms)

Other Operating Income2

Disposal, typically of legacy medicines outside focus

1. Medicines in which AstraZeneca maintains a significant future interest. Revenue through (recurring) milestones and royalty.2. One-off disposal income and legacy royalty income.

15

Emerging markets

Product sales performing strongly

16

Emerging markets: portfolio of diverse markets

Product sales at actual exchange rates and for FY 2019; changes at CER.

$2,211m

+52%

Respiratory& Immunology

New CVRMOncology

$1,175m+10%

Other

$1,986m

+27%

$1,133m

+41%

$2,834m

+4%Asia Pacific

$4,480m+35%

China

$246m+40%

Russia

$1,049m8%

Middle East & Africa

$8,164m+24%

Emerging markets total

$368m+7%

Brazil

$446m+16%

Other Latin America

Proportion of sales

17

Emerging markets: speciality care large opportunity

Specialty care Primary careProduct sales at actual exchange rates and for FY 2019. Speciality care includes Oncology, Brilinta, Lokelma and Fasenra.

60%

40%

56%

44%

67%

33%

47%

53%

USEurope

EMs

Est. RoW

Fast-growing and well-diversified portfolio

18

Emerging markets: top-10 medicines

Product sales at actual exchange rates and for FY 2019; changes at CER.

New medicines Sales 2019 ($m) % change % of total

Tagrisso 762 130 9

Forxiga 471 48 6

Brilique 462 49 6

Older medicines Sales 2019 ($m) % change % of total

Pulmicort 1.190 24 15

Crestor 806 - 10

Nexium 748 14 9

Seloken 686 13 8

Symbicort 547 17 7

Zoladex 492 28 6

Iressa 286 4 4

19

Emerging markets

20

Core profit & loss

Q1 2020$m

change%

% total revenue

Total revenue 6,354 17 100

- product sales 6,311 17 99

- collaboration revenue 43 70 1

Gross margin 78.1% (2.1) pp

Operating expenses1 3,600 8 57

- R&D expenses 1,336 9 21

- SG&A expenses 2,177 7 34

Other operating income 479 (19) 8

Operating profit 1,854 16 29

Tax rate 20%

EPS $1.05 21

Absolute values at actual exchange rates; changes at CER. Gross margin reflects gross profit derived from product sales, divided by product sales. 1. Includes distribution expenses.

Moody’s: A3 Stable outlook / P2 | Standard & Poor’s: BBB+ Stable outlook / A2

21

Debt maturity profile and credit ratings

Notional bond values. FX converted at 30 June 2019 spot rates (USD/EUR 0.89044; USD/GBP 0.78914). Current portion of leases of $206m are included in 2019, whilst non-current leases of $514m have been excluded from the chart.

0

500

1,000

1,500

2,000

2,500

3,000

2019 2020 2021 2022 2023 2024 2025 2027 2028 2029 2031 2037 2042 2045 2048

$m

USD EUR GBP Commercial Paper Overdraft, leases, bank collateral

22

Sustainability matters now more than ever

Some companies fall into the trap of saying ‘we are sustainable’ without asking themselves, what does that really mean? For me, sustainability means being a positive and constructive part of the societies in which we are working. And in a world, that’s changing fast – it matters more than ever.Leif JohanssonChairman of the Board, AstraZeneca

23

Commitment tosustainability

AstraZeneca use its capabilities to make the most meaningful impact where society needs it— health.

The Company believes that there is a strong connection between the health of its business, people and the planet, and each of these impact one another.

AstraZeneca’s commitment to sustainability supports the wider company purpose: Together, we push the boundaries of science to deliver life-changing medicines.

Healthyplanet

Healthypeople

Healthybusiness

+

24

AstraZeneca has well-defined sustainability priorities

Access to Healthcare

Health is at the heartof our business

Environmental Protection

The health of the planetimpacts all life

Ethics and Transparency

Healthy societies promoteequality and prosperity for all

Our ambitionsfor 2025

Address the global burden of NCDs through a holistic approach – from prevention to pipeline to treatment

Manage our environmental impact across all our activities and our products

Create positive societal impact and promote ethical behaviour in all markets across our value chain

Our focus areas

Our UnitedNations SDG

impact

• Investments in health systems• Affordability• Responsible R&D• Environment’s impact on health• Disease prevention and treatment

• Product environmental stewardship• Greenhouse gas reduction• Pharmaceuticals in the environment• Water stewardship• Waste management

• Ethical business culture• Inclusion and diversity• Talent and workforce evolution• Workforce wellbeing and Safety• Responsible supply chain• Human rights

25

Strategy forAccess to Healthcare

We remove barriers to access for people, regardless of social or economic condition

We understand the needs of people and communities living in emerging economies

We develop medicines, create supporting programmes and channel our investments

26

Impact in 2018

12+millionpeople reached

through Healthy Heart Africa, Phakamisa and

Healthy Lung

9.3millionreached through

Patient Assistance Programmes*

3+millionyouth reached through

our Young Health Programme

35,000+healthcare workers

trained*

54 countrieshave active company

initiatives

$686+million

of medicines donated by Patient Assistance

Programmes

27

Strategy forEnvironmental Protection

Our scope 1 and 2 greenhouse gas emissions targets are consistent with reductions required to keep warming to 1.5°C, and our scope 3 target is in line with current best practice.

By investing in new product design,clean technologies and more efficient processes, we save money and resources

We aim to minimise the impact of our products on the environment across the whole of their lifecycle in the face of dwindling natural resources, a growing global population, and climate-related weather events

28

Impact in 2018

$19minvested in environmental

efficiency projects in 2018

61%of our total electricity use

is sourced or generated from renewable

sources

100%of API discharges from

AstraZeneca sitesassessed as safe

>$71mTotal investment in

environmental efficiency projects since 2015

= 7%of our vehicle fleet

in Europe, North America and Japan is hybrid,plug-in or electric,

up from <1% in 2017

We foster an environment that embraces one of our core Values: ‘doing the right thing’

We empower our people to make decisions and speak up if they encounter wrongdoing

In 2017 we launched a Code of Ethics to strengthen understanding of expected behaviours and Global Policies

29

Strategy forEthics and Transparency

30

Impact in 2018

82%of supplier spend was assessed through our

third-party risk management

process

83%of employees feel AstraZeneca is a

great place to work

44.6%of women in Career

Level F roles or higher (senior middle

management)

76%of employees feel that AstraZeneca has a Speak Up

culture

31

Building an exciting company with a vibrant culture

Performing as an

enterprise team

Building a culture

of lifelong learning and development

Champions of inclusion

and diversity

32

Survey results show AstraZeneca has made strong progress

of employees agree AstraZeneca is a Great

Place to Work

84%

of employees agree that their manager

supports diversity and inclusion in the

workplace

86%

of employees have improved their existing skills, or learned new

skills, or had a development

opportunity in the last 12 months

85%

33

Great place to work

Headquarters

Gothenburg, Sweden Gaithersburg, USCambridge, UK

Strategic R&D Centre Strategic R&D Centre

34

AstraZeneca

1. In Q1 2020, speciality-care medicines comprised 49% of total revenue 2. Cardiovascular, Renal and Metabolism.

Improving financials

Nine blockbuster medicines

Returned to sustainablerevenue and earnings growth

Focus on operatingleverage and cash flow

Strong pipeline

17 Phase III medicines and significant lifecycle projects

Advancing early andmid-stage pipeline

Global presence

Balanced specialty1 andprimary-care franchises

Leading emerging marketspresence with R&D base

Innovative medicines in Oncology - CVRM2 - Respiratory & ImmunologyExperienced and proven team

Investor Relations

astrazeneca.com/investors35

Christer Gruvrischrister.gruvris@astrazeneca.comT: +44 20 3749 5711 M: +44 7827 836825

Josie Afolabijosie.afolabi@astrazeneca.comT: +44 20 3749 5631M: +44 7880 400682

Tom Waldrontom.waldron@astrazeneca.comT: +44 7867 975920M: +44 7867 975920

Thomas Kudsk Larsenthomas.larsen@astrazeneca.comT: +44 20 3749 5712M: +44 7818 524185

Nick Stonenick.stone@astrazeneca.comT: +44 20 3749 5716 M: +44 7717 618834

Craig Markscraig.marks@astrazeneca.comT: +44 20 3749 5714M: +44 7881 615764

Henry Wheelerhenry.wheeler@astrazeneca.comT: +44 20 3749 5797M: +44 7788 354619

Jen Kretzmannjennifer.kretzmann@astrazeneca.comT: +44 20 3749 5824M: +44 7469 408333

Rosie Menhinickrosie.menhinick@astrazeneca.comT: +44 20 3749 5509M: +44 7384 806614

Use of AstraZeneca webcast, conference call and presentation slidesThe AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca Materials’) are for your personal, non-commercial use only. Youmay not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sell or otherwise reuse or commercialise the AstraZenecaMaterials in any way. You may not edit, alter, adapt or add to the AstraZeneca Materials in any way, nor combine the AstraZeneca Materials with any othermaterial. You may not download or use the AstraZeneca Materials for the purpose of promoting, advertising, endorsing or implying any connection betweenyou (or any third party) and us, our agents or employees, or any contributors to the AstraZeneca Materials. You may not use the AstraZeneca Materials in anyway that could bring our name or that of any Affiliate into disrepute or otherwise cause any loss or damage to us or any Affiliate. AstraZeneca PLC, 1 FrancisCrick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA. Telephone + 44 20 3749 5000, www.astrazeneca.com